Study on the Treatment of Cardiac Fibrosis by Traditional Chinese Medicine Based on TGF-<i>β</i>1/Smads Signaling Pathway

心脏纤维化是遗传性和获得性心血管疾病(Cardiovascular Disease, CVD)的最终常见病理，导致功能和电生理异常，并同时参与了各种疾病的发展与转归，长期以来一直被视为一种治疗靶点。现有多项研究证实转化生长因子-β (Transforming Growth Factor β, TGF-β)与下游Smad家族所介导的纤维化在心脏纤维化中起着关键作用。以此通路为靶点的中医药研究是目前逆转心脏纤维化的热点。因此，文章以TGF-β1/Smads信号通路为线索，概述近年来中药复方及单味药提取物干预该通路和上下游相关因子，以达到逆转心脏纤维化的作用机制，借以阐明中医药靶向治疗的作用及机制。Cardiac fibrosis is the ultimate common pathology of inherited and acquired cardiovascular disease (CVD), resulting in functional and electrophysiological abnormalities, and is simultaneously involved in the development and outcome of various diseases and has long been regarded as a therapeutic target. A number of studies have confirmed that transforming growth factor β (TGF-β) and downstream Smad family-mediated fibrosis plays a key role in cardiac fibrosis. Currently, the research of traditional Chinese medicine targeting this pathway focuses on reversing cardiac fibrosis. Therefore, in this paper, TGF-β1/Smads signaling pathway clues were used to summarize the mechanism of intervention of TCM compounds and single drug extracts in this pathway and related upstream and downstream factors in recent years to reverse cardiac fibrosis, so as to clarify the role and mechanism of targeted therapy of traditional Chinese medicine.